Logo of thoraxThoraxVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Thorax. Aug 1997; 52(8): 723–730.
PMCID: PMC1758618

Lung surfactant in a cystic fibrosis animal model: increased alveolar phospholipid pool size without altered composition and surface tension function in cftrm1HGU/m1HGU mice


BACKGROUND: Progressive pulmonary dysfunction is a characteristic symptom of cystic fibrosis (CF) and is associated with functional impairment and biochemical alterations of surfactant phospholipids in the airways. However, the fundamental question of whether surfactant alterations in the CF lung are secondary to the pulmonary damage or are present before initiation of chronic infection and inflammation has yet to be resolved in patients with cystic fibrosis but can now be addressed in CF mice that exhibit the basic defect in the airways. A study was therefore undertaken to investigate the pool sizes, composition, and function of lung surfactant in the non-infected cftrm1HGU/m1HGU mouse. METHODS: The amount and composition of phospholipid classes and phosphatidylcholine molecular species were determined in bronchoalveolar lavage (BAL) fluid and lavaged lungs by high performance liquid chromatography (HPLC). Surfactant protein A (SP- A) levels in BAL fluid were determined by ELISA and surfactant for functional measurements was isolated from BAL fluid by differential ultracentrifugation. Equilibrium and minimal surface tension of surfactant was assessed by the pulsating bubble surfactometer technique. MF1, BALB/c, C57/BL6, and C3H/He mice served as controls. RESULTS: BAL fluid of cftrm1HGU/m1HGU mice contained 1.02 (95% confidence interval (CI) 0.89 to 1.16) mumol phospholipid and 259 (239 to 279) ng SP-A. BAL fluid of MF1, BALB/c, C57BL/6, and C3H/He mice contained 0.69 (0.63 to 0.75), 0.50 (0.42 to 0.57), 0.52 (0.40 to 0.64), and 0.45 (0.27 to 0.63) mumol phospholipid, respectively. After correction for the different body weights of mouse strains, phospholipid levels in BAL fluid of cftrm1HGU/m1HGU mice were increased by 64 (52 to 76)%, 60 (39 to 89)%, 72 (45 to 113)%, and 92 (49 to 163)%, respectively, compared with controls. The amount of SP-A in BAL fluid and the composition of phospholipid as well as phosphatidylcholine molecular species in BAL fluid and lung tissue was unchanged in cftrm1HGU/m1HGU mice compared with controls. The increase in phospholipids in BAL fluid of cftrm1HGU/m1HGU mice resulted from an increased fraction of large aggregates which exhibited normal surface tension function. CONCLUSION: In cftrm1HGU/m1HGU mice surfactant homeostasis is perturbed by an increased phospholipid pool in the alveolar compartment.

Full Text

The Full Text of this article is available as a PDF (217K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Galabert C, Jacquot J, Zahm JM, Puchelle E. Relationships between the lipid content and the rheological properties of airway secretions in cystic fibrosis. Clin Chim Acta. 1987 Apr 30;164(2):139–149. [PubMed]
  • McCray PB, Jr, Wohlford-Lenane CL, Snyder JM. Localization of cystic fibrosis transmembrane conductance regulator mRNA in human fetal lung tissue by in situ hybridization. J Clin Invest. 1992 Aug;90(2):619–625. [PMC free article] [PubMed]
  • Engelhardt JF, Zepeda M, Cohn JA, Yankaskas JR, Wilson JM. Expression of the cystic fibrosis gene in adult human lung. J Clin Invest. 1994 Feb;93(2):737–749. [PMC free article] [PubMed]
  • Sugahara K, Iyama K, Sano K, Morioka T. Differential expressions of surfactant protein SP-A, SP-B, and SP-C mRNAs in rats with streptozotocin-induced diabetes demonstrated by in situ hybridization. Am J Respir Cell Mol Biol. 1994 Oct;11(4):397–404. [PubMed]
  • Ulane MM, Butler JD, Peri A, Miele L, Ulane RE, Hubbard VS. Cystic fibrosis and phosphatidylcholine biosynthesis. Clin Chim Acta. 1994 Oct 31;230(2):109–116. [PubMed]
  • van Golde LM. Potential role of surfactant proteins A and D in innate lung defense against pathogens. Biol Neonate. 1995;67 (Suppl 1):2–17. [PubMed]
  • Dorin JR, Dickinson P, Alton EW, Smith SN, Geddes DM, Stevenson BJ, Kimber WL, Fleming S, Clarke AR, Hooper ML, et al. Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature. 1992 Sep 17;359(6392):211–215. [PubMed]
  • Dorin JR, Stevenson BJ, Fleming S, Alton EW, Dickinson P, Porteous DJ. Long-term survival of the exon 10 insertional cystic fibrosis mutant mouse is a consequence of low level residual wild-type Cftr gene expression. Mamm Genome. 1994 Aug;5(8):465–472. [PubMed]
  • BLIGH EG, DYER WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 Aug;37(8):911–917. [PubMed]
  • FOLCH J, LEES M, SLOANE STANLEY GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497–509. [PubMed]
  • BARTLETT GR. Phosphorus assay in column chromatography. J Biol Chem. 1959 Mar;234(3):466–468. [PubMed]
  • Bernhard W, Linck M, Creutzburg H, Postle AD, Arning A, Martin-Carrera I, Sewing KF. High-performance liquid chromatographic analysis of phospholipids from different sources with combined fluorescence and ultraviolet detection. Anal Biochem. 1994 Jul;220(1):172–180. [PubMed]
  • LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed]
  • Wang JY, Yeh TF, Lin YC, Miyamura K, Holmskov U, Reid KB. Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. Thorax. 1996 Sep;51(9):907–913. [PMC free article] [PubMed]
  • Oulton M, MacDonald J, Janigan DT, Faulkner GT. Mouse alveolar surfactant: characterization of subtypes prepared by differential centrifugation. Lipids. 1993 Aug;28(8):715–720. [PubMed]
  • Enhorning G. Pulsating bubble technique for evaluating pulmonary surfactant. J Appl Physiol Respir Environ Exerc Physiol. 1977 Aug;43(2):198–203. [PubMed]
  • Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis. 1993 Jan;147(1):218–233. [PubMed]
  • Doyle IR, Barr HA, Davidson KG, Nicholas TE. Differential changes in SP-A and disaturated phospholipids in the isolated perfused rat lung and in vivo. Am J Physiol. 1996 Sep;271(3 Pt 1):L374–L382. [PubMed]
  • Hamm H, Fabel H, Bartsch W. The surfactant system of the adult lung: physiology and clinical perspectives. Clin Investig. 1992 Aug;70(8):637–657. [PubMed]
  • Marino CR, Gorelick FS. Scientific advances in cystic fibrosis. Gastroenterology. 1992 Aug;103(2):681–693. [PubMed]
  • Chace KV, Leahy DS, Martin R, Carubelli R, Flux M, Sachdev GP. Respiratory mucous secretions in patients with cystic fibrosis: relationship between levels of highly sulfated mucin component and severity of the disease. Clin Chim Acta. 1983 Aug 15;132(2):143–155. [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...